Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study.

abstract：:Previous studies of irinotecan pharmacogenetics have shown that the UGT1A1*28 polymorphism has an effect on irinotecan (IRI)-induced toxicities in Caucasians. Yet compared with the UGT1A1*6 mutation, the UGT1A1*28 occurs at a much lower frequency in the Asians. Whether UGT1A1*6 and UGT1A1*28 are associated with IRI-in...

journal_title：Cancer chemotherapy and pharmacology

authors： Chen X,Liu L,Guo Z,Liang W,He J,Huang L,Deng Q,Tang H,Pan H,Guo M,Liu Y,He Q,He J

更新日期：2017-06-01 00:00:00

abstract：:We have previously reported that multidrug (MDR)-reversal activity can be exerted by compounds in which two ring structures of certain types are connected by one alkyl bridge to a secondary or tertiary amine group. In the present investigation we studied the MDR-reversal activity of compounds in which the two ring str...

journal_title：Cancer chemotherapy and pharmacology

authors： Ramu A,Ramu N

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:Oxaliplatin and satraplatin demonstrate activity against cisplatin-resistant tumor cells. Although the two platinum analogs are structurally-related, oxaliplatin is more active. Therefore, studies focusing on protein expression profiling were undertaken to identify the molecular mechanism for the difference in ...

journal_title：Cancer chemotherapy and pharmacology

authors： He G,Xie X,Siddik ZH

更新日期：2020-06-01 00:00:00

abstract：:Elevations of serum lipid peroxide levels were demonstrated in mice after an equitoxic dose of doxorubicin. When BDF1 mice were injected with doxorubicin (20 mg/kg body weight, IP), lipid peroxide levels in sera were elevated 1 day after the injection and the levels declined on subsequent days. 5-Fluorouracil (400 mg/...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamanaka N,Kato T,Nishida K,Fujikawa T,Fukushima M,Ota K

更新日期：1979-01-01 00:00:00

abstract：:The rate of reaction of monochlorobimane with glutathione (GSH) was measured in native human mammary MCF-7 adenocarcinoma cells (MCF-7wt) and sublines displaying resistance to 4-hydroperoxycyclophosphamide (MCF-7hc) and adriamycin (MCF-7adr) prior to examination by epifluorescence and confocal microscopy. After a 60-m...

journal_title：Cancer chemotherapy and pharmacology

authors： Millis KK,Lesko SA,Gamcsik MP

更新日期：1997-01-01 00:00:00

abstract：PURPOSE:Docetaxel, capecitabine, and cisplatin are effective chemotherapeutic agents for breast cancer with significant synergistic cytotoxicity demonstrated by in vitro studies. The purpose of this study was to assess the efficacy of a combination of docetaxel, capecitabine, and cisplatin (TXP) in patients diagnosed w...

journal_title：Cancer chemotherapy and pharmacology

authors： Lu YS,Chen DR,Tseng LM,Yeh DC,Chen ST,Hsieh CM,Wang HC,Yeh HT,Kuo SH,Huang CS

更新日期：2011-06-01 00:00:00

abstract：PURPOSE:Doxorubicin-based chemotherapy is limited by the development of dose-dependent left ventricular dysfunction and congestive heart failure caused by reactive oxygen species (ROS). Uncoupling proteins (UCP) can inhibit mitochondrial ROS production as well as decrease myocyte damage from exogenous ROS. Prior studie...

journal_title：Cancer chemotherapy and pharmacology

authors： Bugger H,Guzman C,Zechner C,Palmeri M,Russell KS,Russell RR 3rd

更新日期：2011-06-01 00:00:00

abstract：BACKGROUND:The docetaxel/cisplatin (DC) combination is an active regimen against advanced/metastatic non-small-cell lung cancer (NSCLC), and bevacizumab (B) improves the efficacy of frontline chemotherapy. This phase II study was designed in order to explore the efficacy and safety of DCB regiment in this setting. MET...

journal_title：Cancer chemotherapy and pharmacology

authors： Kentepozidis N,Kotsakis A,Soultati A,Agelaki S,Christophylakis Ch,Agelidou M,Chelis L,Papakotoulas P,Vamvakas L,Zafiriou Z,Samonis G,Georgoulias V

更新日期：2013-03-01 00:00:00

abstract：:3-Deazaguanine (3-DG), a purine analogue, has unusual antitumor activity against experimental mammary tumor models and a number of other solid tumors. Others have shown that mutant CHO cells deficient in hypoxanthine guanine phosphoribosyl transferase (HGPRTase) or adenine phosphoribosyl transferase (APRTase) are resi...

journal_title：Cancer chemotherapy and pharmacology

authors： Singh G,Luna MK,Ardalan B

更新日期：1988-01-01 00:00:00

abstract：OBJECTIVE:We evaluated the efficacy and safety of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced metastatic transitional cell carcinoma of the urothelium. SUBJECTS AND METHODS:The subjects were 12 patients diagnosed with advanced metastatic transitional cell carcinoma of th...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamada Y,Itoh Y,Aoki S,Nakamura K,Taki T,Naruse K,Tobiume M,Zennami K,Katsuda R,Kato Y,Watanabe M,Nishikawa G,Minami M,Nakahira M,Ukai S,Sawada M,Kitamura A,Honda N

更新日期：2009-11-01 00:00:00

abstract：:The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin (BCG) for prophylaxis of recurrence of superficial bladder cancer (pTa, pT1) were investigated in 29 patients aged a median of 70 years between January of 1991 and May of 1993. The patients received intravesical instillation of...

journal_title：Cancer chemotherapy and pharmacology

authors： Uekado Y,Hirano A,Shinka T,Ohkawa T

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:To establish the cytochrome P450 (CYP) isozymes involved in the metabolism of the alkylating agent, thiotepa, to the pharmacologically active metabolite, TEPA. METHODS:In vitro chemical inhibition studies were conducted by incubating thiotepa and pooled human hepatic microsomes in the presence of known inhibit...

journal_title：Cancer chemotherapy and pharmacology

authors： Jacobson PA,Green K,Birnbaum A,Remmel RP

更新日期：2002-06-01 00:00:00

abstract：:New 4'-C-methyl analogues of daunorubicin, synthesized by the coupling reaction of daunomycinone with 1-chloroderivatives of protected 4-C-methyldaunosamine analogues, were chemically transformed to the corresponding doxorubicin analogues. Their cytotoxic effect against HeLa cells, ability to bind to DNA, and in vivo ...

journal_title：Cancer chemotherapy and pharmacology

authors： Bargiotti A,Casazza AM,Cassinelli G,Di Marco A,Penco S,Pratesi G,Supino R,Zaccara A,Zunino F,Arcamone F

更新日期：1983-01-01 00:00:00

abstract：PURPOSE:An intact and fully functional multiprotein DNA replication complex (DNA synthesome) from human as well as from murine mammary carcinoma cells was first isolated and characterized in our laboratory. The human cell synthesome supports the in vitro origin-specific simian virus 40 (SV40) DNA replication reaction i...

journal_title：Cancer chemotherapy and pharmacology

authors： Abdel-Aziz W,Jiang HY,Hickey RJ,Malkas LH

更新日期：2000-01-01 00:00:00

abstract：:The full-scale commercial appearance of antibiotics in the 1950s caused a shift in the nature of lethal diseases from infectious and acute to noninfectious and chronic. In this situation, biological response modifiers (BRMs), which are not based on selective toxicity, could be expected to be useful. Several types of B...

journal_title：Cancer chemotherapy and pharmacology

authors： Hashimoto Y

更新日期：2003-07-01 00:00:00

abstract：PURPOSE:To evaluate the feasibility, toxicity and efficacy of the combination of docetaxel and mitomycin C as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS:Thirty-eight patients with histologically confirmed, locally advanced or metastatic NSCLC were includ...

journal_title：Cancer chemotherapy and pharmacology

authors： Feliu J,Martín G,Castro J,Sundlov A,Rodriguez-Jaráiz A,Casado E,Lomas M,Madroñal C,Galán A,Belda C,Gonzalez-Barón M

更新日期：2006-10-01 00:00:00

abstract：PURPOSE:To assess the safety of the association of radiotherapy (RT) and systemic treatments for patients with metastatic malignant melanoma (mMM). METHODS:A retrospective analysis included consecutive patients treated with palliative RT, and at least one line of systemic therapy for mMM between 2001 and 2016. Treatme...

journal_title：Cancer chemotherapy and pharmacology

authors： Couty E,Vallard A,Sotton S,Ouni S,Garcia MA,Espenel S,Rancoule C,Ben Mrad M,Biron AC,Perrot JL,Langrand-Escure J,Magné N

更新日期：2019-05-01 00:00:00

abstract：:Thirty-three patients with advanced transitional cell carcinoma of the urinary tract (23 bladder cases, 8 ureter cases, and 2 renal pelvis cases) were treated by three-drug combination chemotherapy using two protocols (protocol I: Adriamycin 50 mg/m2, cyclophosphamide 500 mg/m2, and 5-fluorouracil 500 mg/m2, protocol ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kotake T,Usami M,Miki T,Kuroda M,Obata K,Osafune M,Fujioka H,Takasugi Y

更新日期：1983-01-01 00:00:00

abstract：:Deoxycoformycin (dCF) is a promising new antineoplastic agent in the treatment of lymphoid malignancies, particularly hairy cell leukemia (HCL). Skin toxicity in the form of a maculopapular eruption has previously been reported but has not clearly been associated with idiosyncratic reactions. We present five cases of ...

journal_title：Cancer chemotherapy and pharmacology

authors： O'Dwyer PJ,King SA,Eisenhauer E,Grem JL,Hoth DF

更新日期：1989-01-01 00:00:00

abstract：:The antimetabolite 1-beta-D-arabinofuranosyl-cytosine (ara-C) has proven to be one of the most effective agents available for the treatment of acute leukemia. While ara-C has been implicated as a potent inhibitor of mammalian cell DNA replication, the specific mechanism by which ara-C kills cells is not known. In this...

journal_title：Cancer chemotherapy and pharmacology

authors： Wills P,Hickey R,Ross D,Cuddy D,Malkas L

更新日期：1996-01-01 00:00:00

abstract：PURPOSE:To evaluate the antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a vascular disrupting agent currently under phase II clinical trials in combination with cancer chemotherapy, in rats bearing chemically induced primary mammary tumours. METHODS:Tumours were induced in female Wistar rats by in...

journal_title：Cancer chemotherapy and pharmacology

authors： Liu JJ,Ching LM,Goldthorpe M,Sutherland R,Baguley BC,Kirker JA,McKeage MJ

更新日期：2007-04-01 00:00:00

abstract：PURPOSE:Gemcitabine (2',2'-difluorodeoxycytidine) is an antineoplastic agent with activity against a variety of solid tumors. To investigate its in vitro activity toward cervical cancer, we exposed six cervical cancer cell lines to gemcitabine. METHODS:Combinational cytotoxic studies using viability tests and clonogen...

journal_title：Cancer chemotherapy and pharmacology

authors： Hernández P,Olivera P,Dueñas-Gonzalez A,Pérez-Pastenes MA,Zárate A,Maldonado V,Meléndez-Zajgla J

更新日期：2001-12-01 00:00:00

abstract：:A total of 51 patients with large, primary, high-grade soft-tissue sarcomas of the extremities were treated at our institute with two preoperative and three postoperative cycles of doxorubicin plus ifosfamide/mesna. Preoperative doxorubicin was given intra-arterially for lesions of the lower extremities. Of 47 evaluab...

journal_title：Cancer chemotherapy and pharmacology

authors： Azzarelli A,Quagliuolo V,Casali P,Fissi S,Montalto F,Santoro A

更新日期：1993-01-01 00:00:00

abstract：PURPOSE:To investigate the activity and tolerance of pegylated liposomal doxorubicin in combination with vinorelbine in pretreated patients with metastatic breast cancer. PATIENTS AND TREATMENT:Thirty-six women with metastatic breast cancer were enrolled. The median age was 64 years, 80% of the patients had a performa...

journal_title：Cancer chemotherapy and pharmacology

authors： Ardavanis A,Mavroudis D,Kalbakis K,Malamos N,Syrigos K,Vamvakas L,Kotsakis A,Kentepozidis N,Kouroussis C,Agelaki S,Georgoulias V,Breast Cancer Committee of the Hellenic Oncology Research Group.

更新日期：2006-12-01 00:00:00

abstract：PURPOSE:To evaluate the safety and efficacy of paclitaxel in elderly patients with advanced non-small-cell lung cancer (NSCLC). METHODS:We compared the toxicity, response, survival and pharmacokinetic parameters between patients between 70 and 75 years of age (elderly group) and those under 70 years of age (younger gr...

journal_title：Cancer chemotherapy and pharmacology

authors： Nakamura Y,Sekine I,Furuse K,Saijo N

更新日期：2000-01-01 00:00:00

abstract：BACKGROUND:The oral PARP inhibitor olaparib has shown efficacy in patients with BRCA-mutated cancer. This Phase I, open-label, three-part study (Parts A-C) in patients with advanced solid tumours evaluated the effect of food on the pharmacokinetics (PK) of olaparib when administered in tablet formulation. METHODS:PK d...

journal_title：Cancer chemotherapy and pharmacology

authors： Plummer R,Swaisland H,Leunen K,van Herpen CM,Jerusalem G,De Grève J,Lolkema MP,Soetekouw P,Mau-Sørensen M,Nielsen D,Spicer J,Fielding A,So K,Bannister W,Molife LR

更新日期：2015-10-01 00:00:00

abstract：:2'-deoxycoformycin (2'-dCF; Pentostatin), a stoichiometric inhibitor of mammalian adenosine deaminase (ado deaminase), exhibits immunosuppressive and antilymphocytic activity in animal test systems. A clinical pharmacology/phase I study of 2'-dCF administered as a single agent has been completed (18 patients). Dose le...

journal_title：Cancer chemotherapy and pharmacology

authors： Smyth JF,Paine RM,Jackman AL,Harrap KR,Chassin MM,Adamson RH,Johns DG

更新日期：1980-01-01 00:00:00

abstract：:Forty-three previously untreated patients, all of whom had poor-prognosis small cell lung cancer and/or were greater than 65 years old, received treatment with vindesine and VP16-213. Thirteen patients had limited disease and 30 extensive disease. Response rates (CR + PR) of 86% (CR 29%) and 66% (CR 17%) were seen in ...

journal_title：Cancer chemotherapy and pharmacology

authors： Allan SG,Gregor A,Cornbleet MA,Leonard RC,Smyth JF,Grant IW,Crompton GK

更新日期：1984-01-01 00:00:00

abstract：PURPOSE:To investigate any effect of a CYP3A4 inhibitor (ketoconazole) or inducer (rifampicin) on cediranib steady-state pharmacokinetics in patients with advanced solid tumours. METHODS:In two Phase I, open-label trials, patients received once-daily oral doses of cediranib alone [20 mg (ketoconazole study); 45 mg (ri...

journal_title：Cancer chemotherapy and pharmacology

authors： Lassen U,Miller WH,Hotte S,Evans TR,Kollmansberger C,Adamson D,Nielsen DL,Spicer J,Chen E,Meyer T,Brown K,Rafi R,Sawyer MB

更新日期：2013-02-01 00:00:00

abstract：PURPOSE:Ridaforolimus, a potent inhibitor of the mammalian target of rapamycin (mTOR), is under development for the treatment for solid tumors. This open-label, randomized, 3-period crossover study investigated the effect of food on the pharmacokinetics of ridaforolimus 40 mg as well as safety and tolerability of the s...

journal_title：Cancer chemotherapy and pharmacology

authors： Stroh M,Li X,Marsilio S,Panebianco D,Johnson-Levonas A,Juan A,Orford K,Agrawal N,Trucksis M,Wagner JA,Murphy G,Iwamoto M

更新日期：2012-07-01 00:00:00